E
SGTX

Ergoteles’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Ergoteles’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,374
Closed -$15.3K – 1958
2022
Q4 		$15.3K Sell
3,374
-1,486
-31% -$8.48K ﹤0.01% 1355
2022
Q3 		$32K Sell
4,860
-644
-12% -$5.88K ﹤0.01% 1464
2022
Q2 		$59K Buy
+5,504
New +$74K ﹤0.01% 1552

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's SGTX Position: Q1 2023 in Review

Ergoteles sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2023, closing a stake of 3,374 shares — an estimated $15.3K sold.

Ergoteles first reported a position in SGTX in Q2 2022 and held it in 3 quarters. The position peaked at $59K in Q2 2022. 32 funds tracked by Wall St. Rank hold SGTX as of Q1 2023.

  • Ergoteles reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 3,374 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $15.3K.
  • Ergoteles first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Sigilon Therapeutics, Inc. Common Stock position peaked at $59K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.